MSD is spending up to $1 billion to embed Google Cloud's Gemini Enterprise across its entire operation, the largest known agentic AI deal in the pharmaceutical industry. The multi-year partnership, announced April 22 at Google Cloud Next in Las Vegas, will deploy an agentic platform across MSD's research and development, manufacturing, commercial and corporate functions. Google Cloud engineers will work alongside MSD teams to integrate Gemini Enterprise and a portfolio of specialized agents, including the newly launched Deep Research agent that autonomously plans and executes multi-step R&D tasks.
MSD (known as Merck & Co. in the US and Canada) employs 75,000 people worldwide. The company is entering what chief information and digital officer Dave Williams called "one of the most significant launch periods in our company's history," with AI agents and generative tools expected to help reimagine processes at scale. The deal signals a shift in how big pharma approaches AI. Rather than deploying point solutions for specific use cases, MSD is building what Google Cloud CEO Thomas Kurian described as an "industry-first agentic ecosystem" designed to touch every part of the drugmaking value chain: from R&D workflows and manufacturing optimization through predictive analytics to commercial operations and patient engagement.
MSD will house Google Cloud workers alongside its own teams as the partnership plays out, embedding technical expertise directly into the drugmaker's operations. The Gemini Enterprise platform gives MSD access to pre-built agents such as Deep Research, which comes in two versions (standard for speed, Max for highest-quality context gathering) and allows scientists to combine open-source web data with proprietary internal information in a single application.
The announcement comes as Google Cloud pushes aggressively into enterprise AI at its annual conference. The same day, Google announced a separate $750 million partner fund aimed at consulting firms and systems integrators that build agents on its platform, with Accenture (450+ agents built), Deloitte (its "largest investment yet" in any cloud AI platform), and KPMG ($100 million commitment) among those signing on. The competitive market is crowded.
Microsoft announced its own partner initiative the day before Cloud Next, OpenAI formed its Frontier Alliances program with McKinsey, BCG and Accenture in February 2026, and Anthropic reportedly plans to invest $200 million in a private equity venture to embed Claude into portfolio companies. But MSD's billion-dollar commitment gives Google Cloud a marquee pharma reference that no competitor can match on scale.
For MSD, the bet is that embedding AI agents across every function will accelerate drug development timelines during a period when the company faces both expiring patents on blockbuster drugs like Keytruda (which loses exclusivity in 2028) and a pipeline of new products entering late-stage trials. Williams said AI agents will help "bring scientific breakthroughs to patients faster."
